Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib). IMBRUVICA™ is now also indicated for the treatment of patients with Chronic Lymphocytic Leukemia (CLL) who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established.
Dosing for CLL
The recommended dose of IMBRUVICA™ for CLL is 420 mg (three 140 mg capsules) orally once daily.
IMBRUVICA™ is commercially available immediately through Onco360 and its network of OncoMed Pharmacies. Orders can be placed by:
- Downloading an IMBRUVICA™ Order Form at www.Onco360.com and faxing it to 877-662-6355;
- Calling 877-662-6633; or
- e-Prescribing to OncoMed, The Oncology Pharmacy.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV